PROTOCOL |
AA-DESCRIPTION-AA |
NUM |
CALG-B (LARSON) INDUCTION |
ALL (Acute Lymphoblastic Leukemia)
REFER: Larson RA, et al: PROC ASCO 1992; 11:263.
CYCLOPHOSPHAMIDE 1200 mg/m2 IV D1
DAUNORUBICIN 45 mg/m2 per day IV D1-3
VINCRISTINE 1.4 mg/m2 IV D1,8,15,22
PREDNISONE 60 mg/m2 per day PO...D1-21
L-ASPARAGINASE 6000 iu/m2 IV D5,8,11,15,18,22 |
226 |
MidAC5+3 |
AML (Acute Myeloid Leukemia) - MRC Protocol
Trial: AML 15
MITOXANTRONE 10MG/M2 d1-5
CYTATABINE 2 G/M2 d1-3 |
137 |
ADE
10/8+3+5 |
AML - MRC protocol
Trials: AML 15 AND AML HR
CYTARABINE 200MG/M2 10(8)DAY
DAUNORUBICIN 50MG/M2 D1,3,5
ETOPOSIDE 100MG/M2 5 DAYS |
102 |
DA 3+8/10 |
AML - MRC Protocol
Trial: MRC AML 15
DAUNORUBICIN 50MG/M2 D 1,3,5
CYTARABINE 200MG/M2 D 1-8/10
|
135 |
A+D(7+3) |
AML - variant of DAT
REFER: Dillman RO, et al: BLOOD 1991; 78:2520-2526.
DAUNORUBICIN 45 MG/M2/DAY d1-3(2)
CYTARABINE 100 MG/M2/DAY d1-7(5) |
227 |
ADE(7+3+7)
INDUCTION |
AML
REF: Bishop J, et al: BLOOD 1990; 1/1 75(1):27-32.
CYTARABINE 100 mg/m2 per day CIV D1-7
DAUNORUBICIN 50 mg/m2 per day IV D1-3
ETOPOSIDE 75 mg/m2 D1-7 |
228 |
MC INDUCTION |
AML
REF: Arlin Z, et al: LEUKEMIA 1990; 4:177-183.
MITOXANTRONE 12 mg/m2 IV D1-3
CYTARABINE 100 mg/m2 CIV D1-7 |
232 |
FLAG-Ida |
AML - MRC Protocol
Trial: AML 15
IDARUBICIN 10 MG/M2/DAY d4-6
CYTARABINE 2 G/M2/DAY d2-6
FLUDARABINE 30MG/M2/DAY d2-6 G-CSF (LENOGRASTIM)
263 UG SC DAY 1-7 |
130 |
IDA-AR2
CONSOL |
AML
REF: Vogler WR, et al: J CLIN ONCOL 1992;
10:1103-1111.
THIOGUANINE 100 mg/m2 PO BD D1-5
CYTARABINE 100 mg/m2 IV BD D1-5
IDARUBICIN 15 mg/m2 IV D1 |
231 |
IDA-AR1 INDUCTION |
AML
REF: Vogler WR, et al: J CLIN ONCOL 1992;
10:1103-1111.
IDARUBICIN 12 mg/m2 IV D1-3
CYTARABINE 100 mg/m2 CIV D1-7 |
230 |
HiDAC |
AML
REF: Bloomfield CD, Herzig GP, eds.:
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA 1993; 7:47-79.
CYTARABINE 1.5-3 g/m2 IV BD D1-4(6) |
229 |
High-dose Ara-C |
AML - MRC Protocol
Trial: AML 15
CYTARAABINE 1.5 OR 3.0 G/M2 BD d1, 3, 5 |
139 |
Gemtuzumab
MYLOTARG |
Gemtuzumab (MYLOTARG)
9 MG/M2
DAY 1
|
131 |
DAT |
AML - MRC Protocol; & variants
Trial: AML 9?
DAUNORUBICIN 50 MG/M2/DAY d1(3)(5)
CYTARABINE 200 MG/M2/DAY d1-(5)(7)(10)
THIOGUANINE 200MG/M2/DAY d1-(5)(7)(10) |
113 |
D50A400 |
AML - MRC Protocol; variant of DAT
Trial: AML 14
DAUNORUBICIN 50 MG/M2/DAY d1-3
CYTARABINE 400 MG/M2/DAY d1-8(10)
THIOGUANINE 200MG/M2/DAY d1-8(10) |
128 |
D35A200 |
AML - MRC Protocol; variant of DAT
Trial: AML 14
DAUNORUBICIN 35 MG/M2/DAY d1-3
CYTARABINE 200 MG/M2/DAY d1-8(10)
THIOGUANINE 200MG/M2/DAY d1-8(10) |
129 |
MAC |
AML
Mitozantrone 12mg/m2 d1,3,(5)
Cytarabine 200mg/m2/day d1-5 |
117 |
ICE 2+3 |
AML - MRC Protocol
Trial AML 14
IDARUBICIN 10MG/M2 d1,2
CYTARABINE 200 MG/M2 d1-3
ETOPOSIDE 100MG/M2 d1-3 |
134 |
MACE |
AML - MRC Protocol
Trials: AML 15
AMSACRINE 100MG/M2 5 d1-5
CYTARABINE 200MG/M2 5 d1-5
ETOPOSIDE 100MG/M2 5 d1-5 |
136 |
FLA(G) |
AML - MRC Protocol
Trials: AML 12 & HR
FLUDARABINE 30MG/M2 d1-5
CYTARABINE 2G/M2 d1-5
+/- G-CSF 5ug/kg/day +/- ATRA 45 mg/m2/day |
140 |
D50A200 |
AML - MRC Protocol; variant of DAT
Trial: AML 14
DAUNORUBICIN 50 MG/M2/DAY d1-3
CYTARABINE 200 MG/M2/DAY d1-8(10)
THIOGUANINE 200MG/M2/DAY d1-8(10) |
127 |
D35PA400 |
AML - MRC Protocol; variant of DAT
Trial: AML 14
DAUNORUBICIN 35 MG/M2/DAY d1-3
PSC833 32 mg/kg 72 hr inf d1-3
CYTARABINE 400 MG/M2/DAY d1-8(10)
THIOGUANINE 200MG/M2/DAY d1-8(10) |
132 |
ICE 3+5 |
AML - MRC Protocol
Trial AML 12
IDARUBICIN 10MG/M2 d1-3
CYTARABINE 200 MG/M2 d1-5
ETOPOSIDE 100MG/M2 d1-5 |
133 |
FU-MMC-XRT |
Anus
REF: Tanum G, et al: CANCER 1991; 67:2462-2466.
FLUOROURACIL 1000 mg/m2 CIV D1-4
MITOMYCIN C 10 - 15 mg/m2 IV D1
Concomitant XRT q 28d |
221 |
SMF |
Pancreatic Ca
REF:
Streptozotocin 1000mg/m2 Week 1,2,5,6
Fluorouricil 600 mg/m2 IV week 1,2,5,6
Mitomycin C 10 mg/m2 IB D1 Q56 d |
223 |
MVAC |
BLADDER CA - TRANSITIONAL CELL
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 224-225.
METHOTREXATE 30 mg/m2 IV D1,15,22
VINBLASTINE 3 mg/m2 IV D2,15,22
DOXORUBICIN 30 mg/m2 IV D2
CISPLATIN 70 mg/m2 IV D2 q 28d |
225 |
EP |
Cervix Cancer - non small cell
ETOPOSIDE 60 mg/m2 IV D1-3
ETOPOSIDE 50 mg/m2 PO d4-10
CISPLATIN 30 mg/m2 per day IV D1-3
q28d
|
270 |
MACE |
Gestational Trophoblastic Carcinoma - High Risk
ETOPOSIDE 100 mg po D1-10
Actinomycin D 0. 50 mg/m2 PO d8,9
Methotrexate 400 mg/m2 d8
CISPLATIN 30 mg/m2 per day IV D1-3
q14d
|
275 |
MTX+DACT |
Gestational Trophoblastic Carcinoma - Low Risk
Dactinomycin 0.60 mg/m2 PO d1,2
Methotrexate 400 mg/m2 d8 V D1-3
q14d
|
276 |
EP |
Testicular Cancer
ETOPOSIDE 100 mg/m2 per day IVD1-5
(reduce by 20% if
prior XRT)
CISPLATIN 20 mg/m2 per day IV D1-5
q21d
|
243 |
FP |
GU Tract Ca SQUAMOUS
carcinoma of Penis
GI Tract Ca Oesophageal Cancer
Fluorouricil 1000 mg/m2 per day IV inf D1-4
CISPLATIN 25 mg/m2 per day IV D1-3
q28d
|
244 |
FUC |
GI Tract Ca Oesophageal, Stomach,
Gall bladder Cancer, cholangiocarcinoma
Fluorouricil 1000 mg/m2 per 24h IV inf D1,2
CISPLATIN 25 mg/m2 od IV D1
q7
|
255 |
Mitomycin C |
Prostate Cancer -
Adenocarcinoma
Mitomycin C 12 mg/m2
IV d1 q28
|
246 |
Mitoxantrone
+ Prednisolone |
Prostate Cancer -
Adenocarcinoma
Mitoxantrone C 12 mg/m2
IV d1
Prednisolone 10 mg
d1-21 q21
|
247 |
Doxorubicin |
Thyroid - Medullary Carcinoma
GI Tract - Hepatoma (Metastatic)
Doxorubicin 60 mg/m2 d1 q21 |
250 |
Gemcitabine |
Pancreas Adenocarcinoma
Ref: Skeel R Handbook of Cancer
Chemotherapy, 5th Ed, Lipincott Williams and Wilkins 1999,
p109
Gemcitabine 1000 mg IV
D1,8,15,22,29,36,43 q 49
|
257 |
Cisplatin + Gemcitabine |
LUNG - mesothelioma
CISPLATIN 75 mg/m2 IV D1
Gemcitabine 1250 IV D1,8 q
21
|
268 |
Cisplatin + Gemcitabine |
Bladder - Urothelial
CISPLATIN 70 mg/m2 IV D1
Gemcitabine 1000 IV
D1,8,15 q 28
Alternative:
CISPLATIN 70 mg/m2 IV D1
Gemcitabine 1250 IV
D1,8 q 21
|
241 |
Gemcitabine |
Ovarian - Epithelial Cell
Gemcitabine 800 IV
D1,8,15 q 28
|
274 |
Carboplatin + Gemcitabine |
Bladder - Urothelial
CARBOPLATIN (5 X (GFR + 25)) mg IV
D1
Gemcitabine 1000 IV
D1,8,15 q 28
Alternative:
Carboplatin (5 x (GFR +25)) mg IV D1
Gemcitabine 1250 IV
D1,8 q 21
|
242 |
Carboplatin |
Seminoma - Stage 1 high risk
CARBOPLATIN (7 X (GFR + 25)) mg IV
D1 q 28 - two cycles
|
248 |
Topotecan |
Ovarian - Epithelial
Topotecan 1.25 mg/m2 IV
D1-5 q 21
|
273 |
Carboplatin |
Ovarian - Epithelial
CARBOPLATIN (6 X (GFR + 25)) mg IV
D1 q 28
|
272 |
Raltitrexed |
Colorectal Carcinoma
Raltitrexed 3 mg/m2 IV q21 |
258 |
CMV |
Bladder
REF: Harker WG, et al: J CLIN ONCOL 1985;
3:1463-1470.
CISPLATIN 100 mg/m2 IV D2
METHOTREXATE 30 mg/m2 IV D1,8
VINBLASTINE 4 mg/m2 IV D1,8 Q 21d |
224 |
BCNU |
BRAIN
CARMUSTINE 80 mg/m2 IV D1-3 Q 6-8 wks
REFER: Walker MD, et al: J NEUROSURG 1978;
49:333-343. |
212
|
CCNU |
BRAIN
LOMUSTINE 130 mg/m2 po D1 Q 6 wks
|
260
|
PCV |
BRAIN TUMOURS
REF: Levin VA, et al: INT J RADIAT ONCOL BIOL PHYS
1990; 18:321-324.
LOMUSTINE 110 mg/m2 PO D1
PROCARBAZINE 60 mg/m2 per day PO D8-21
VINCRISTINE 1.4 mg/m2 IV D8, 22 Q6-8 weeks |
213 |
CCV |
BRAIN TUMOURS
LOMUSTINE 75 mg/m2 PO D1
CISPLATIN 75 mg/m2 per day IV D1
VINCRISTINE 1.4 mg/m2 IV D1,8,15 Q6 weeks |
261 |
PROC |
BRAIN
REFER:
PROCARBAZINE 100 mg/m2 PO D1-14 Q28D |
214 |
Saltz |
Colorectal Cancer
REF: Saltz et al. New Eng J. Med. 343 (13) 905-14,
2000
Irenotecan 100 or 125 mg/m2 IV d1,8,15,22
Folinic Acid 20 mg/m2 IV d1,8,15,22 Fluorouricil
400 or 500 mg/m2 Iv d1,8,15,22 q 42d |
185 |
Degramont |
Colorectal Cancer
REF: Douillard JY et al. The Lancet 355: 1041-47,
2000
Irenotecan 185 mg/m2 IV d1
Folinic Acid 200 mg/m2 IV d1 Fluorouricil
400 mg/m2 Iv d1 bolus then 600mg/m2 22 h inf d1 q14 |
269 |
|
|
|
Irenotecan |
Colorectal Cancer
Irenotecan 350 mg/m2 IV d1 q15 OR
Irenotecan 125 mg/m2 IV d1,8,15,22 q21
|
256 |
GO9502 |
BCCA Protocol Summary for Treatment of
Small Cell Carcinoma of Cervix Using Paclitaxel, Cisplatin,
Etoposide and Carboplatin with Radiation (GO 95 02)
CYCLE
|
A
|
B
|
C
|
D
|
E
|
DAY
|
1
|
2
|
21
|
22
|
23
|
24
|
25
|
42
|
56
|
70
|
84
|
98
|
126
|
127
|
128
|
129
|
130
|
1paclitaxel
175
mg/m2 IV
|
x
|
|
|
|
|
|
|
|
|
|
|
x
|
|
|
|
|
|
2cisplatin
60
mg/m2 IV
|
x
|
x
|
x
|
x
|
|
|
|
x
|
x
|
x
|
x
|
|
|
|
|
|
|
3etoposide
75
mg/m2 IV
|
|
|
x
|
x
|
|
|
|
|
|
|
|
|
|
|
|
|
|
etoposide 100 mg PO
|
|
|
|
|
x
|
x
|
x
|
|
|
|
|
|
x
|
x
|
x
|
x
|
x
|
4carboplatin
IV
|
|
|
|
|
|
|
|
|
|
|
|
x
|
x
|
|
|
|
|
5 pelvic/para-aortic XRT 4000 cGy in 25#;
selectron x2 or lat. pelvis 1000 cGy in 5#
|
|
|
|
|
|
|
186 |
PACLITAXEL |
Breast Cancer, Stage IV
Ovarian Cancer - Epithelial
REF: TAXOL(R) (paclitaxel) Bristol-Myers Squibb Co,
prescribing info in PHYSICIANS DESK REFERENCE 49th Ed. Montvale, NJ;
1995;682.
Paclitaxel (Taxol) 175 mg/m2 IV over 3hrs d1 q21 |
145 |
PACLITAXEL + CARBOPLATIN |
Endometrial Cancer
Paclitaxel (Taxol) 175 mg/m2 IV d1
Carboplatin 6x(GFR+25) mg IV q21 |
271 |
AC |
Breast Cancer, Stage I-IV
Cyclophosphamide 600mg/m2 d1
Doxorubicin 60 mg/m2 d1 q21 |
143 |
CMFP |
Breast Cancer, Stage I-IV
Marschke RF, et al: CANCER 1989; 63:1931-1937.
Cyclophosphamide 100 mg/m2 po
d1-14
Methotrexate 30 mg/m2 iv d1,8
Fluorouricil 600 (modified) mg/m2 d1,8
PREDNISONE 40 mg/m2 PO D1-14 q28 |
181 |
CAF(IV) |
Breast Cancer, Stage I-IV
REF: Smalley RV, et al: A Southeastern Cancer Study
Grp Prj: CANCER 1977; 40:625-632.
Cyclophosphamide 500 mg/m2 IV d1
Doxorubicin 50 mg/m2 IV d1 or over 72h inf
Fluorouricil 500 mg/m2 IV d1 q21 |
178 |
CEF |
Breast Cancer, Stage I-IV - BCCA protocol
Cyclophosphamide
75 mg/m2 PO d1-14
Epirubicin 60 mg/m2 IV d1,8
Fluorouricil 500 mg/m2 IV d1,8 q28 |
234 |
Trastuzamab |
Breast Cancer Trastuzamab (Herceptin)
Trastuzamab 8 mg/kg first cycle
6mg/kg subsequent cycles q21 |
238 |
Trastuzamab +
Paclitaxel |
Breast Cancer Trastuzamab + Pacletaxel
Trastuzamab 8 mg/kg d1 Paclitaxel 175mg/m2 d2 -
1st cycle
Trastuzamab 6 mg/kg d1 Paclitaxel 175mg/m2
d1 - cycles
2-6 q21 |
239 |
Trastuzamab +
Vinorelbine |
Breast Cancer Trastuzamab + Vinorelbine
Trastuzamab 4 mg/kg Vinorelbine 25mg/m2 - first
week
Trastuzamab 4 mg/kg Vinorelbine 25mg/m2 -
subsequent weeks q7 |
240 |
FAC |
Breast Cancer, Stage I-IV
REF:
Hortobagyi GH, et al: CANCER 1989; 63:37-45.
Cyclophosphamide 500
mg/m2 IV d1
Doxorubicin 50 mg/m2 IV (modified) d1
Fluorouricil 500 mg/m2 IV d1,8 (modified)
q21/28 |
144 |
Docetaxel + Cisplatin |
Lung Cancer - non small cell
Docetaxel (Taxotere) 75 mg/m2 IV d1 Cisplatin
75 mg/m2 IV d1 q21 |
263 |
Docetaxel |
Lung Cancer - non small cell
Docetaxel (Taxotere) 75 mg/m2 IV d1 q21 |
264 |
Docetaxel |
Breast Cancer
Docetaxel (Taxotere) 100 mg/m2 IV d1 q21 |
146 |
Docetaxel(weekly) |
Breast Cancer
Docetaxel (Taxotere) 35 mg/m2 IV d1 q8 |
237 |
CAD |
Breast Cancer, Stage IV
Docetaxel (Taxotere) 75 mg/m2 IV d1
Capecitabine 1000-1250 mg/m2 po bd q21 |
235 |
Docetaxel |
Prostate Cancer - hormone refractory
Docetaxel (Taxotere) 75 mg/m2 IV d1 q21 |
245 |
Capecitatbine |
Breast Cancer
Colorectal Cancer
Capecitabine 1000-1250 mg/m2 po bd d1-14 q21 |
236 |
MF |
Breast Cancer, Stage I-IV
Methotrexate 100 mg/m2 IV d1,8
Fluorouricil 600 mg/m2 IV d1,8
Folinic Acid 10 mg/m2 IV/po qid x6 doses d2,9 q28 |
184 |
CNF |
Breast Cancer
REF: Bennett JM, et al: J CLIN ONCOL 1988;
6:1611-1620.
CYCLOPHOSPHAMIDE 500 mg/m2 IV D1
MITOXANTRONE 10 mg/m2 IV D1
FLUOROURACIL 500 mg/m2 IV
D1 q 21d |
182 |
CAF(PO) |
Breast Cancer, Stage I-IV
REFER: Skeel RT: Handbook of Cancer Chemotherapy,
3rd Ed. Little, Brown & Co. 1991.
CYCLOPHOSPHAMIDE100 mg/m2 PO D1-14
DOXORUBICIN 30 mg/m2 IV
FLUOROURACIL 500 mg/m2 IV
D1,8 q28 |
179 |
CMF(PO)
Classical |
Breast Cancer, Stage I-IV
REF: Bonadonna G, et al: NEJM 1976; 294:405-410.
Cyclophosphamide 100 mg/m2 po
d1-14
Methotrexate 40 mg/m2 iv d1,8
Fluorouricil 600 mg/m2 d1,8 q28 |
141 |
CMF(PO)E |
Breast Cancer, Stage I-IV
REF: Bonadonna G, et al: NEJM 1976; 294:405-410.
Cyclophosphamide 100 mg/m2 po d1-14
Methotrexate 30 mg/m2 iv d1,8
Fluorouricil 600 (modified) mg/m2 d1,8 q28 |
180 |
CMF(IV) |
Breast Cancer, Stage I-IV
REF: Weiss RB, et al: AM J MED 1987; 83:455-463.
Cyclophosphamide 600 mg/m2 IV d1
Methotrexate 40 mg/m2 IV d1
Fluorouricil 600 mg/m2 IV d1 q21 |
142 |
FAC
(BOLUS) |
Breast Cancer, Stage I-IV
REF: Blumenschein G, et al: PROC ASCO 1974; 15:193.
Cyclophosphamide 500 mg/m2 IV d1
Doxorubicin 50 mg/m2 IVB d1
Fluorouricil 500 mg/m2 IV d1,8 q21 |
183 |
VINORELBINE
(weekly) |
Breast Cancer
Vinorelbine 30mg/m2 IV weekly |
148 |
VINORELBINE |
Breast Cancer
Lung Cancer: Non Small Cell - palliative
Vinorelbine 30mg/m2 IV d1,8 q21 |
147 |
CDDP |
Cervical Cancer
REF: Skeel RT: Handbook of Cancer Chemotherapy, 5th
Ed. Lippincott Williams and Wilkins. 1999; 282-3.
CISPLATIN [CDDP] 50 mg/m2 IV/30 min d1 q 21d |
173 |
BOMP |
Cervical Cancer
REF: Vogl SE, et al: CANCER TREAT REP. 1980;
64:1005-1007.
VINCRISTINE 1 mg/m2 (max 2) IV D1,8,22,29
BLEOMYCIN
10 units (10,000 iu) IM weekly
CISPLATIN 50 mg/m2 IV/1h D1,22
MITOMYCIN-C 10 mg/m2 IVB D1 q 42d |
172 |
BIP |
Cervical Cancer
REFER: Buxton EJ: ACTA ONCOL 1988; 27:545-549.
BLEOMYCIN 30 units (30,000 iu) CIV over 24 hrs D1
IFOSFAMIDE 5
g/m2 CIV over 24 hrs
D2
CISPLATIN 50 mg/m2 IV D2
MESNA [MESNA] 8 g/m2 CIV over 36 hrs...D2 q21 |
171 |
Fludarabine iv |
CLL/ Low grade NHL
Ref: Skeel RT; Handbook of cancer chemotherapy, 5th
Ed Lippincott, Williams and Wilkins 1999; 107-8.
Fludarabine 25 mg/m2 d1-5 q28 |
124 |
FluCyclo |
CLL - MRC Protocol: Trial CLL4
Ref: O'Brien et al J Clin Oncol 19.
5:1414-20;2001
Fludarabine 25mg/m2 IV
d1-3
OR 24mg/m2 PO
d1-5 q28
Cyclophosphamide 250 mg/m2 IV d1-3
OR
150 mg/m2 PO d1-5 q28 |
125 |
FU-LEVAM |
Colorectal cancer
REF: Moertel CG, et al: NEJM 1990; 322:352-358.
LEVAMISOLE 50 mg tid PO D1-3 d15-17
FLUOROURACIL 450 mg/m2 per day D1-5
Then at D28 begin
FLUOROURACIL 450 mg/m2 IV weekly x 48 weeks
LEVAMISOLE 50 mg tid PO D1-3 fortnightly x 48 weeks
CYCLE: Total Therapy - 1 year. |
167
|
FU/LV#1 |
Colorectal Cancer
REF: Petrelli N, et al: J CLIN ONCOL 1989;
7:1419-1426.
Folinic Acid 500 mg/m2 Weeks 1-6
FLUOROURACIL [5-FU] 600 mg/m2 IV weeks 1-6 at
midpoint of Leucovorin infusion |
168 |
FU/LV#2 |
Colorectal Cancer
Ref: Maroun JA et al. Am J Clin Oncol. 20(4):378-92, 1997.
FLUOROURACIL [5-FU] 370 mg/m2 IV D1-5
Folinic Acid [Leu] 200 mg/m2 IV D1-5 q28
|
169 |
FU/LV#3 |
Colorectal Cancer
Ref: Ardalan, et al: J CLIN ONCOL 1991; 9:625-630
FLUOROURACIL 2600 mg/m2 d1 24 hrs inf CIV
Folinic Acid 500 mg/m2 d1 24 hrs inf CIV q7 |
170 |
FU/LV#4 |
Colorectal Cancer
BCCA Protocol
FLUOROURACIL [5-FU] 425 mg/m2 IV D1-5
Folinic Acid [Leu] 20 mg/m2 IV D1-5 q28
|
252 |
FOLFIRI |
Colorectal Cancer
BCCA Protocol
Irenotecan 180 mg/m2 d1
FLUOROURACIL [5-FU] 400 + 2400 mg/m2 IV D1-2
Folinic Acid [Leu] 200 mg/m2 IV D1 q14
|
253 |
FOLFOX |
Colorectal Cancer
BCCA Protocol
Oxaliplatin 100
mg/m2 d1
FLUOROURACIL [5-FU] 400 + 2400 mg/m2 IV D1-2
Folinic Acid [Leu] 400 mg/m2 IV D1 q14
|
254 |
LIPOSOMAL
DOXORUBICIN |
Cutaneous: Kaposi's
REF: Northfeld DW et al, J Clin Onc (15) 653-9, 1997
LIPOSOMAL DOXORUBICIN 20 mg/m2 IV/ D1 q21d |
233 |
VP-16 |
Cutaneous: Kaposi's
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 373.
ETOPOSIDE 150 mg/m2 IV/4-6hr D1-3 q28d |
216 |
HDI |
Cutaneous: Melanoma
Ref: Kirkwood JM, Ibrahim JG, Sosman JA, et
al. J Clin Oncol 2001;19(9):2370-80
Interferon 2b 20 MU/m2 d1-5 IV q7 - 4
cycles then
Interferon 2b 10MU/m2 sc
Mon/Wed/Fri x 48w |
277 |
VDP |
Cutaneous: Melanoma
REF: Nathanson L: Melanomas ... In: Skeel RT, ed.
Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown & Co.
1991; 256.
VINBLASTINE 5 mg/m2 IV D1,2
DACARBAZINE 150 mg/m2 IV D1-10
CISPLATIN 75 mg/m2 IV D5 Q21/28D |
220 |
Cisplatin+
Dacarbazine |
Cutaneous: Melanoma
REF: Albino AP, et al. Chapter 41:
Malignant Melanoma. In: DeVita V. T. HS, Rosenberg
S.A., ed. Cancer: Principles & Practice of Oncology
- 5th Edition. Philadelphia: Lippincott-Raven
Publishers, 1997:1935 - 2011.
DACARBAZINE 850 mg/m2 IV D1
CISPLATIN 100 mg/m2 IV D1 q21d
|
278 |
DBPT |
Cutaneous: Melanoma
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 256.
DACARBAZINE 220 mg/m2 IV D1-3 q 21d
CISPLATIN 25 mg/m2 IV D1-3 q21d
CARMUSTINE 150 mg/m2 IV D1 q42d
TAMOXIFEN 10 mg PO bd |
217 |
ABV |
Cutaneous: Kaposi =s
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 373.
DOXORUBICIN 40 mg/m2 IV D1
BLEOMYCIN 15000 iu/m2 IV D1,15
VINBLASTINE 6 mg/m2 IV D1 q28d |
215 |
BORTEZOMIB (Velcade) |
Haematology: Myeloma
REF:
BORTEZOMIB 1.3 mg/m2 IV D1,4,8,11 Q 21 D |
281 |
DTIC3 |
Cutaneous: Melanoma
REF:
DACARBAZINE 1100 mg/m2 IV D1 Q 21 D |
279 |
DTIC2 |
Cutaneous: Melanoma
REF: DeVita VT Jr, et al: Cancer Principles and
Practice of Oncology 3rd Ed. J.B.Lippincott Co. 1989; 1637.
DACARBAZINE 850 mg/m2 IV D1 Q 21/28 D |
219 |
DTIC1 |
Cutaneous: Melanoma
REF: DeVita VT Jr, et al: Cancer Principles and
Practice of Oncology 3rd Ed. J.B.Lippincott Co. 1989; 1522.
DACARBAZINE 250 mg/m2 IV D1-5 q21d |
218 |
PAC-2 |
Endometrial Cancer
REF: Turbow MM, et al: PROC ASCO 1982; 1:108.
CISPLATIN 60 mg/m2 D1
DOXORUBICIN 50 mg/m2 D1
CYCLOPHOSPHAMIDE 600 mg/m2D1 q21/28 |
166 |
MCA |
Endometrial Cancer
REF: Horton J, et al: CANCER 1982; 49:2441-2445.
MEGESTROL 80 mg TID PO od
CYCLOPHOSPHAMIDE [CTX] 400 mg/m2 IVB...D1
DOXORUBICIN 40 mg/m2 IVB D1 q 28 days |
159 |
PFL |
Head and Neck
REF: Dreyfuss AI, et al: ANN INTERN MED 1990;
112:167-172.
CISPLATIN 25 mg/m2 CIV D1-5
FLUOROURACIL 800 mg/m2 CIV D2-6
LEUCOVORIN 500 mg/m2 CIV D1-6 Q28D |
211 |
MBC |
Head and Neck
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 153.
METHOTREXATE 40 mg/m2 IM/IV D1,15
BLEOMYCIN 10000 iu IM/IV D1,8,15
CISPLATIN 50 mg/m2 IV D4 q21d |
210 |
COB |
Head and Neck
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 152. CISPLATIN mg/m2 IV...D1
VINCRISTINE 1 mg IV D2,5
BLEOMYCIN 30000 iu CIV D2-5 q21 |
209 |
CF |
Head and Neck
REFER: Kish JA, et al: CANCER 1985; 56:2740-2744.
CISPLATIN 100 mg/m2 IV D1
FLUOROURACIL 1000 mg/m2 4 CIV D1-4 q21d |
208 |
PABLOE |
Hodgkin =s
Dis - BNLI/UKLG/MRC protocol
Trial:
Doxorubicin 40 mg/m2 d1
Vincristine 1.4 mg/m2 D1,8
Bleomycin 10,000 iu/m2 d1,8
Prednisolone 40mg/m2 d1-10
Etoposide 200mg/m2 d1-3 |
118 |
VAPEC-B |
Hodgkin =s
Dis - BNLI/UKLG/MRC protocol
Trial: LY07
Prednisolone 50 mg od d1-28
Doxorubicin 35mg/m2 d1; Cyclophosphamide 350 mg/m2
d1
Vincristine 1.4 mg/m2 d8,22;
bleomycin 10000 iu/m2
d8,22
Doxorubicin 35 mg/m2 d15; etoposde 100 mg/m2 d15-19 |
123 |
ABVD |
Hodgkin =s
Dis - BNLI/UKLG/MRC protocol
Trials: LYO
Doxorubicin 25 mg/m2 d1 & d15
Bleomycin 10 mg/m2 (10,000 iu/m2) d1 & d15
Vinblastine 6 mg/m2 d1 & d 15
Dacarbazine 375 mg/m2 d1 & d15 |
101 |
ChlVPP |
Hodgkin =s
Dis - BNLI/UKLG/MRC protocol
Trial LY09
Chlorambucil 6 mg/m2 days 1-14
Procarbazine 100 mg/m2 (max 200) days 1-14
Prednisolone 40 mg/m2 days 1-14
Vinblastine 6 mg/m2 days 1&8 |
104 |
Stanford V |
Hodgkin =s
Dis -
Mustine 6 mg/m2 w 1, 5, 9
Doxorubicin HCl 25mg/m2 w 1, 3, 5, 7, 9
Vinblastine 6 mg/m2 w 1, 3, 5, 7,
9
Etoposiide 60 mg/m2 d1,2 of w 3, 7, 11
Prednisolone 40 mg/m2 alt day 12 weeks
Vincristine 1.4 mg/m2 w 2, 4, 6, 8, 10, 12
Bleomycin 5000iu /m2 w 2, 4, 6, 8, 10,
12 |
138 |
BEACOPP (standard/baseline) |
Hodgkin =s
Disease -
Cyclophosphamide 650 mg/m2 d1
Doxorubicin HCl 25mg/m2 d1
Etoposide 100 mg/m2 d1,2, 3
Bleomycin 10mg/m2 d8
Vincristine 1.4 mg/m2 (max 2) d8
Procrbazine 100 mg/m2 D1-7
Prednisolone 40 mg/m2 D1-14 q21
|
283 |
BEACOPP ESCALATED |
Hodgkin =s
Disease -
Cyclophosphamide 1250 mg/m2 d1
Doxorubicin HCl 35mg/m2 d1
Etoposide 200 mg/m2 d1,2, 3
Bleomycin 10mg/m2 d8
Vincristine 1.4 mg/m2 (max 2) d8
Procrbazine 100 mg/m2 D1-7
Prednisolone 40 mg/m2 D1-14 q21
|
284 |
ICE |
Non-Hodgkin's Lymphoma - CORAL TRIAL Ifosfamide 5 g/sqm
d1 24h infusion
Etoposide 100 mg/sqm d1, d2 d3
Carboplatin 5 AUC (max 800 mg) D2 q21 |
282 |
Rituximab
(rituxan)
(mabthera)
(anti-cd20) |
Non-Hodgkin =s
Lymphoma -
Rituximab 375 mg/sqm IV
|
112 |
MVP |
Lung: Non Small Cell
REF: Bonomi PD, et al: J CLIN ONCOL 1989;
7:1602-1613.
MITOMYCIN C 10 mg/m2 IV D1
VINBLASTINE 6 mg/m2 IV D1
CISPLATIN 40 mg/m2 IV D1 q 21d |
192 |
FED |
Lung: Non Small Cell
REF: Sridhar KS, et al: SEMIN IN SURG ONCOL 1993;
9:114-119.
CISPLATIN 100 mg/m2 IV/over 3-4 hrs D1
ETOPOSIDE 80 mg/m2 IV D2,3,4
FLUOROURACIL 960 mg/m2 CIV...D2,3,4 Q 21D |
191 |
CDDP+VP16 |
Lung: Non Small Cell
REF: Longeval E, et al: CANCER 1982; 50:2751-2756.
CISPLATIN 60 mg/m2 IV D1
ETOPOSIDE 100 mg/m2 IV D4,6,8 (OR D3,5,7) q 21/28d |
190 |
CBDCA+VP16 |
Lung: Non Small Cell
REF: Klastersky JP: J CLIN ONCOL 1990; 8:1556-1562.
CARBOPLATIN 325 mg/m2 IV D1
ETOPOSIDE 100 mg/m2 IV D1-3 q 28d |
189 |
CBDCA+VP16 |
Brain: Ependymoma
CARBOPLATIN 300 mg/m2 IV D1
ETOPOSIDE 100 mg/m2 IV D1 q 28d |
259 |
Cisplatin +
Pemetrexed |
Lung: Mesothelioma
CISPLATIN 75 mg/m2 IV D1
PEMETREXED 500 mg/m2 IV D1 q21d |
266 |
CAP |
Lung: Non Small Cell
REF: Eagan RT, et al: CANCER TREAT REP 1979;
63:1589-1591.
CYCLOPHOSPHAMIDE 400 mg/m2 IV D1
DOXORUBICIN 40 mg/m2 IV D1
CISPLATIN 60 mg/m2 IV D1 Q 28D |
188 |
CAE |
Lung: Small Cell
REF: Rudolph A, et al: PROC ASCO 1983; 2:192.
CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1
DOXORUBICIN 45 mg/m2 IV D1
ETOPOSIDE [VP-16] 50 mg/m2 IV D1-5 q21d |
196 |
CAV |
Lung: Small Cell
REF: Roth BJ, et al: J CLIN ONCOL 1992; 10:282-291.
CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1
DOXORUBICIN 40 mg/m2 IV D1
VINCRISTINE 1 mg/m2 (max 2 mg)IV D1 q 21d |
197 |
VIP(ICE)-2
(VIPP) |
Lung: Non Small Cell
REF: Perez EA, et al: Cancer Cbemotherapy and
Pharmacology 34(4): 331-4, 1994
IFOSFAMIDE 1 - 1.2 g/m2 IV D1-3
MESNA 0.4 g/m2 PO/IV qid
CISPLATIN 100 mg/m2 IV D1,8
ETOPOSIDE 60 - 75 mg/m2 IV D1-3 q 28d |
195 |
PVP-16 |
Lung: Non Small Cell
REF: Klastersky J: SEMIN IN ONCOL 1986; 13(Suppl
3):104-114.
CISPLATIN 60 - 120 mg/m2 IV D1
ETOPOSIDE 50 - 120 mg/m2 IV D1-3 q 21/28d |
194 |
NVB-CDDP |
Lung: Non Small Cell
REF: LeChevalier T, et al: J CLIN ONCOL 1994;
12:360-367.
Vinorelbine (Navelbine) 30mg/m2 IV D1,8,15,22,29,35
Cisplatin 120 mg/m2 D1,29 q 42d |
193 |
NAVP |
Lung: Non Small Cell
Vinorelbine (Navelbine) 30mg/m2 IV d1,8
Cisplatin 30 mg/m2 D1,8 q 21d |
265 |
VINORELBINE |
Lung: Non Small Cell
REF: LeChevalier T, et al: J CLIN ONCOL 1994;
12:360-367.
Vinorelbine (Navelbine) 30mg/m2 IV weekly |
147 |
PAVE |
Lung: Small Cell
CISPLATIN 30 mg/m2 IV D1
DOXORUBICIN 40 mg/m2 IV D1
ETOPOSIDE 100 mg/m2 PO d3,5
VINCRISTINE 1mg/m2 IV D1 q 21d |
267 |
CAVE |
Lung: Small Cell
REF: DeVore RF, et al: Current Therapy in
Hematology-Oncology. Brain MC,
Carbone PP,eds. 4th Ed. B.C.Decker 1992;274-278.
CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1
DOXORUBICIN 50 mg/m2 IV D1
ETOPOSIDE 50 mg/m2 d1-5
VINCRISTINE 1.5 mg/m2 (max 2mg) D1 q 21d |
198 |
VIP(ICE)-1 |
Lung: Small Cell
REF: Faylona E, et al: PROC ASCO 1992; 11:307.
IFOSFAMIDE 1.2 g/m2 IV D1-4 with MESNA
CISPLATIN 20 mg/m2 per day IV D1-4
ETOPOSIDE 37.5 mg/m2 PO D1-5 Q 28d |
201 |
EP |
Lung: Small Cell
REF: DeVore RF, et al: Current Therapy in
Hematology-Oncology. Brain MC, Carbone PP,eds. 4th Ed. B.C.Decker
1992;274-278. CISPLATIN 25 mg/m2 IV D1-3
ETOPOSIDE 100 mg/m2 IV D1-3 Q21D |
200 |
CEV |
Lung: Small Cell
REF: Comis RL: SEMIN IN ONCOL 1986; 13(Suppl
3):40-44.
CYCLOPHOSPHAMIDE 1000 mg/m2 IV D1
VINCRISTINE 1.4 mg/m2 IV D1 (max 2mg)
ETOPOSIDE 50 mg/m2 IV D1
ETOPOSIDE 100 mg/m2 PO D2-5 Q21D |
199 |
CAMP |
Lung: Non Small Cell
REF: Bitran JD, et al: CANCER TREAT REP 1976;
60:1225-1230. CYCLOPHOSPHAMIDE 300 mg/m2 IV D1,8
DOXORUBICIN 20 mg/m2 IV D1,8
METHOTREXATE 15 mg/m2 IV D1,8
PROCARBAZINE 100 mg/m2 per day PO D1-10 q 28 d |
187 |
C-WEEKLY |
Multiple Myeloma - MRC protocol
Trial MYELOMA VIII
Cyclophospamide 400 mg/m2 po weekly
Prednisolone 40 mg/m2 po alt day |
103 |
VAD |
Multiple Myeloma
Dexamethasone 40 mg/day d1-4
Vincristine 0.4mg/d 96 hr infusion
doxorubicin 9mg/m2 96 hr infusion |
122 |
ABCM |
Multiple Myeloma - MRC protocol
Trials: MYELOMA VII & VIII
Adriamycin 30mg/m2 and BCNU 30mg/m2
day 1
Melphalan 6 mg/m2 and cyclophosphamide
100mg/m2 days 22-26 q42 |
100 |
C-VAMP |
Multiple Myeloma - MRC protocol
Trial: Myeloma VII
Doxorubicin 9 mg/m2/day 96hr inf d1-4
Vincristine 0.4 mg/day 96 hr inf d1-4
Methylprednisolone 1g/m2 d1-5
Cyclophosphamide 500 mg d1,8,15 q21 |
111 |
CIDEX |
Multiple Myeloma Rel - Riverside protocol
CCNU 40mg d1;
Idarubicin 10 mg/m2 po d1-3
Dexamethasone 10 mg bd d1-4 q21 |
106 |
MACOP-B |
NHL
REF: Connors JM, et al (eds). Update on Treatment
for Diffuse Large Cell Lymphoma. Wiley & Sons 1986; 37-43.
METHOTREXATE 400 mg/m2 IV weeks 2,6,10
LEUCOVORIN 15 mg PO QID 6 DOSES, start 24hr after
MTX
DOXORUBICIN 50 mg/m2 IV weeks 1,3,5,7,9,11
CYCLOPHOSPHAMIDE 350 mg/m2 IV weeks 1,3,5,7,9,11
VINCRISTINE 1.4 mg/m2 IV weeks 2,4,6,8,10,12
BLEOMYCIN [BLEO] 10OOO iu/m2 IV weeks 4,8,12
PREDNISONE [Pred] 75 mg per day PO Tapered over last
15 days |
156 |
C-VAD
(CVAD)
|
MULTIPLE MYELOMA
REF: MRC MYELOMA IX TRIAL
Dexamethasone 40 mg/day d1-4 AND d12-15
Vincristine 0.4mg/d 96 hr infusion
doxorubicin 9mg/m2/d 96 hr infusion
cyclophosphamide mg PO/IV D1,8,15 q21
|
152 |
CVP-1 |
NHL
REF: Bagley CM, et al: ANN INTERN MED 1972;
76:227-234
CYCLOPHOSPHAMIDE 400 mg/m2 OD PO D1-5
VINCRISTINE 1.4 mg/m2 IV D1
PREDNISONE100 mg/m2 per day PO D1-5 Q21 |
153 |
MIV |
NHL
REF: Herbrecht R, et al: PROC ASCO 1991; 10:278.
MITOXANTRONE 10 mg/m2 IV D1
IFOSFAMIDE 1500 mg/m2 per day IV D1-3 With MESNA
ETOPOSIDE 150 mg/m2 per day IV D1-3 q21 |
157 |
IV |
IV for Brain Tumour
IFOSFAMIDE 5000 mg/m2 IV D1 With MESNA
ETOPOSIDE 100 mg/m2 per day IV D1,2 q21 |
262 |
PMitCEBO |
NHL High Grade - BNLI/UKLG/MRC protocol
Trial: Sixty Plus
prednisolone 50-25 mg/day d1-14
Mitizantrone 7 mg/m2 d1
Etoposide 150 mg/m2 d1
Cyclophosphamide 300 mg/m2 d1
Vincristine 1.4 mg/m2 d8
Bleomycin 10000 iu/m2 d8 |
121 |
MiniBEAM |
NHL High Grade relapse
Carmustine 60 mg/m2 d1
Cytarabine 100 mg/m2 d2-5
Etoposide 75 mg/m2 d2-5
Melphalan 30 mg/m2 d6 |
149 |
m-BACOD |
NHL
REF: Shipp MA, et al: ANN INTERN MED 1986;
104:757-765.
METHOTREXATE 200 mg/m2 IV D8,15
Folinic acid 10 mg/m2 PO D9,16 qid x doses
BLEOMYCIN 4000 iu/m2 IV D1
DOXORUBICIN 45 mg/m2 IV D1
CYCLOPHOSPHAMIDE 600 mg/m2 IV D1
VINCRISTINE 1 mg/m2 IV D1
DEXAMETHASONE 6 mg/m2 per day PO D1-5 q21 |
158 |
BEAM |
NHL High Grade relapse
Carmustine 300 mg/m2 d1
Cytarabine 200 mg/m2 d2-5
Etoposide 200 mg/m2 d2-5
Melphalan 140 mg/m2 d6 |
150 |
ESAP |
NHL High Grade relapse
REF: Velasquez W, et al: PROC ASCO 1989; 8:256
METHYLPREDNISOLONE 500 mg per day IV D1-4
ETOPOSIDE 40 mg/m2 per day IV D1-4
CYTARABINE 2 g/m2 IV D5
CISPLATIN [CDDP] 25 mg/m2 per day x 4 CIV D1-4 |
155 |
DHAP |
NHL High Grade relapse
REF: Velasquez WS, et al: BLOOD 1988; 71:117-122.
CISPLATIN 100 mg/m2 CIV over 24 hrs D1
CYTARABINE [ARA-C] 2 g/m2 IV bd D2
DEXAMETHASONE 40 mg per day PO or IV D1-4 q21 or q28 |
154 |
COP-X |
NHL High Grade, relapse - Nexstar protocol
Cyclophosphamide 750 mg/m2 d1
Liposomal daunorubicin 100 mg/m2 d1
Vincristine 1.4 mg/m2 d1
Prednisolone 100 mg od d1-5 q21 |
110 |
ESHAP |
NHL High Grade, Relapse
Ref: Aparicio J et al. ESHAP is an active
regimen for relapsing Hodgkin's disease. Annals of Oncology 10(5);
593-5,1999
Methlyprednisolone 250 mg d1-5
Cisplatinum 25mg/m2/day d1-4
Etoposide 40mg/m2/day d1-4
Cytarabine 2g/m2 d5 |
114 |
CHOP |
NHL High Grade - BNLI/UKLG/MRC protocol
Trial: LY02; Sixty plus
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 343.
Cyclophosphamide 750 mg/m2 d1
Doxorubicin 50 mg/m2 d1
Vincristine 1.4 mg/m2 d1
Prednisolone 100 mg od d1-5 q21 |
105 |
CNOP |
NHL HIGH GRADE
Variant of CHOP
Cyclophosphamide 750 mg/m2 d1
Mitozantrone 12 mg/m2 d1
Vincristine 1.4 mg/m2 d1
Prednisolone 100 mg od d1-5 q21 |
108 |
PACEBO |
NHL High Grade - BNLI/UKLG/MRC protocol
Trial: Sixty Plus
Prednisolone 50-25 mg/day d1-14
Doxorubicin 35 mg/m2 d1
Etoposide 150 mg/m2 d1
Cyclophosphamide 300 mg/m2 d1
Vincristine 1.4 mg/m2 d8
Bleomycin 10000 iu/m2 d8 |
119 |
COP (CVP) |
NHL HIGH GRADE
Variant of CHOP
Cyclophosphamide 750 mg/m2 d1
Vincristine 1.4 mg/m2 d1
Prednisolone 100 mg od d1-5 q21 |
109 |
FAD |
NHL Low Grade - BNLI/UKLG/MRC protocol
Trial: ?
Fludarabine 25mg/m2/day d1-3
Doxorubicin 50 mg/m2 d1
Dexamethasone 20mg/day d1-5 q21 |
115 |
PROMACE-
CYTABOM |
NHL
REF: Fisher RI, et al: PROC ASCO 1984; 242.
Abstract.
PREDNISONE 60 mg/m2 per day PO D1-14
DOXORUBICIN 25 mg/m2 IV D1
CYCLOPHOSPHAMIDE 650 mg/m2 IV D1
ETOPOSIDE 120 mg/m2 IV D1
CYTARABINE 300 mg/m2 IV D8
BLEOMYCIN 5000 iu/m2 IV D8
VINCRISTINE 1.4 mg/m2 IV D8
METHOTREXATE 120 mg/m2 IV D8
LEUCOVORIN 25 mg PO D9 qidx 4 doses q21 |
160 |
CHOP-BLEO |
NHL High Grade - BNLI/UKLG/MRC protocol
REF: Rodriguez V, et al: BLOOD 1977; 49:325-333.
Cyclophosphamide 750 mg/m2 d1
Doxorubicin 50 mg/m2 d1
Vincristine 1.4 mg/m2 d1,5 (max 2 mg)
Prednisolone 100 mg od d1-5
Bleomycin 15,000 iu od d1-5 q14 or q21 |
151 |
FMD |
NHL LOW Grade - BNLI/UKLG/MRC protocol
Fludarabine 25mg/m2/day d1-3
Mitoxantrone ?12 mg/m2 d1
Dexamethasone 20mg/day d1-5 q21 |
116 |
PACEBOM |
NHL High Grade - BNLI/UKLG/MRC protocol
Trial:
Prednisolone 50-25 mg/day d1-14
Doxorubicin 35 mg/m2 d1
Etoposide 150 mg/m2 d1
Cyclophosphamide 300 mg/m2 d1
Vincristine 1.4 mg/m2 d8
Methotrexate 100 mg/m2 d8
Bleomycin 10000 iu/m2 d8 |
120 |
CIOP |
NHL High Grade - BNLI/UKLG/MRC protocol
Variant of CHOP
Cyclophosphamide 750 mg/m2 d1
Idarubicin 10 mg/m2 d1
Vincristine 1.4 mg/m2 d1
Prednisolone 100 mg od d1-5 q21 |
107 |
FU-PB-MMC |
Oesophageal Cancer
CYCLE: Given with radiation - See reference.
REF: Leichman L, et al: J CLIN ONCOL 1987;
5:365-370.
CISPLATIN 100 mg/m2 IV at 1mg/min D1,29
FLUOROURACIL 1000 mg/m2 CIV... D1-4,29-32
MITOMYCIN-C 10 mg/m2 IV bolus D57
BLEOMYCIN 20,000 iu CIV D57-60, 78-81 |
165
|
CDDP-FU-XRT |
Oesophageal Cancer
REF: Herskovic A et al NEJM 1992, 326; 1593-8.
FLUOROURACIL 1000 mg/m2 CIV d1-4
CISPLATIN 75 mg/m2 IV/1mg/min D1 q21/28 |
164
|
FU-XRT |
Pancreas
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 181.
FLUOROURACIL 500 mg/m2 D1-3, 29-31, XRT
FLUOROURACIL 500 mg/m2 FROM D 71 WEEKLY |
222 |
HDMTX |
Sarcoma: Bony/Osteo
REF: Perry MC: The Chemotherapy Sourcebook. Williams
& Wilkins 1992; 766.
METHOTREXATE 8-12 g/m2 (max 20g)
Monitor urine pH and MTX plasma concentrations
carefully
Folinic Acid 15-25 mg PO/IV qid 10 doses starting
24hrs post MTX q14/28d |
203 |
A-DIC |
Sarcoma: Soft Tissue
REFER: Baker LH et al J Clin Oncol 1987; 5:851-861.
DOXORUBICIN 60 mg/m2 IV D1
DACARBAZINE 250 mg/m2 IV 1h D1 q21d |
204 |
AC |
Sarcoma: Bony/Osteo
REF: Skeel RT: Handbook of Cancer Chemotherapy, 3rd
Ed. Little, Brown & Co. 1991; 279.
DOXORUBICIN 75 - 90 mg/m2 CIV/96h D1-4
CISPLATIN 120 mg/m2 IA or IV D6 Q 28D |
202 |
CYVADIC |
Sarcoma: Soft Tissue
REF: Yap B-S, et al: CA TREAT REP 1980; 64:93-98.
CYCLOPHOSPHAMIDE 400-500 mg/m2 IV D1
Vincristine 1.5 mg/m2 (Max 2mg) d1,5
DOXORUBICIN 45-60 mg/m2 IV D1
DACARBAZINE 200-250 mg/m2 IV 1h D1-5 q21d |
206 |
CYADIC |
Sarcoma: Soft Tissue
REFER: Baker LH, et al: J CLIN ONCOL 1987;
5:851-861.
CYCLOPHOSPHAMIDE 400-500 mg/m2 IV D1
DOXORUBICIN 45-60 mg/m2 IV D1
DACARBAZINE 200-250 mg/m2 IV 1h D1-5 q21d |
205 |
MAID |
Sarcoma: Soft Tissue
REF: Elias AD, et al: PROC ASCO 1987; 6:134.
MESNA 2500 mg/m2 CIV D1-4
DOXORUBICIN 20 mg/m2 CIV D1-3
IFOSFAMIDE 2500 mg/m2 IV D1-3
DACARBAZINE 300 mg/m2 CIV D1-3 q21d |
207 |
EFP |
Small Bowel/GASTRIC CANCER
REF: Ajani J, Sixth Int Conf on the Adj ther of
Cancer, Proc & Abstracts 1990; 396-404
ETOPOSIDE 90 mg/m2 per day IV D1,3,5
CISPLATIN 20 mg/m2 IV D1-5
FLUOROURICIL 900 mg/m2 CIV
over 2 hrs D1-5 Q24-28 |
162 |
EAP |
Small Bowel/GASTRIC CANCER
REF: Preusser P, et al: J CLIN ONCOL 1989;
7:1310-1317.
ETOPOSIDE 120 mg/m2 per day IV D4-6
DOXORUBICIN 20 mg/m2 IV D1,7
CISPLATIN 40 mg/m2 IV
over 2 hrs D2,8 Q21-28 |
161 |
FAM |
Small Bowel/GASTRIC CANCER
REF: MacDonald JS, et al: ANN INTERN MED 1980;
93:533-536.
FLUOROURACIL 600 mg/m2 D1,8,29,36
DOXORUBICIN 30 mg/m2 D1,29
MITOMYCIN-C 10 mg/m2 IV D1
Q56 |
163 |
PVB |
Testicular Cancer
REF: Williams SD, et al: NEJM 1987; 316:1435-1440.
VINBLASTINE 0.15 mg/kg IV D1,2(reduce by 20% if
prior XRT)
CISPLATIN 20 mg/m2 per day IV D1-5
BLEOMYCIN 30,000 iu IV D2,9,16 q 21d |
175 |
VIP-1 |
Testicular Cancer
REF: Loehrer PJ, et al: ANN INTERN MED 1988;
109:540-546.
ETOPOSIDE 75 mg/m2 IV D1-5
IFOSFAMIDE 1.2 g/m2 x 5 CIV D1-5
CISPLATIN 20 mg/m2 IV D1-5
MESNA 400 mg/m2 IV D1 15 min. pre ifos
MESNA 1.2 g/m2 per day x 5 CIV D1-5 q21d |
176 |
VIP-2 |
Testicular Cancer
REF: Loehrer PJ, et al: ANN INTERN MED 1988;
109:540-546.
VINBLASTINE 0.11 mg/kg d1,2
IFOSFAMIDE 1.2 g/m2 ?x 5 CIV D1-5
CISPLATIN 20 mg/m2 IV D1-5
MESNA 400 mg/m2 IV D1 15 min. pre ifos
MESNA 1.2 g/m2 per day x ?5 CIV D1-5 q21d |
177 |
BEP |
Testicular Cancer
Ovarian Cancer - Germ Cell
REF: Williams SD, et al: NEJM 1987; 316:1435-1440.
ETOPOSIDE 100 mg/m2 per day IVD1-5(reduce by 20% if
prior XRT)
CISPLATIN 20 mg/m2 per day IV D1-5
BLEOMYCIN 30,000 iu IV D2,9,16 q 21d |
174 |